# Janssen: Committed to Immunology





### Our mission is to transform individual lives

3 million people in Europe suffer from rheumatoid arthritis 1

4 million people in Europe suffer from psoriatic arthritis 2, 3, 4, 5

14 million people in Europe suffer from psoriasis 2



**Janssen** is currently working to

psoriasis and psoriatic arthritis

So far,

3 of the 5 approved biologic treatments

for psoriasis or psoriatic arthritis were developed by

Johnson Johnson



But we are committed to

### researching and treating more immune-mediated diseases

which are estimated to affect between

40 and 60 million people in Europe,

which is around

5-7% of the European population 6,7



# We have a culture of collaboration

Janssen Pharmaceutica N.V. joined the Johnson & Johnson family of companies in 1961




been recognised as one most innovative and prol

Janssen Europe, Middle East & Africa (EMEA) has...



4.000 employees



We work closely with leading experts in their field to

bring innovative ideas and therapies from the lab to the clinic and to patients in need





# We aim to support and empower

Janssen is at the forefront of programmes aimed at improving standards of care and empowering patients to take control of their condition

#### Read this! 'A framework for improving the quality of care for people with psoriasis'

# **The European Psoriasis White Paper**

A multinational, multidisciplinary collaboration between 9 authors from 6 European countries



Authored by the European **Expert Working Group for** 



Healthcare in Psoriasis (EEWGHP)

Published in the Journal of the European Academy of Dermatology and Venereology (JEADV)

Sign the Mandate! I believe that each person living with psoriasis has a right to:



1. Early and 2. Access to a 3. Access to accurate specialist for regular diagnosis treatment



countrie

The Psoriasis

**Mandate** 

effective treatment offers

5. Understanding

and support from

society to live a

normal life




4. Involvement and choice in a treatment plan with defined goals



www.psoriasis360.com **/psoriasis-mandate** 

#### Psoriasis360.com Visit the website!

Psoriasis360.com provides people with psoriasis with the knowledge and tools, to take a more pro-active role in managing their condition



This site is published by Janssen Pharmaceutica, NV. It is intended for a European audience.




# We would like to hear from you

To find out more or to contact us...

Find out

Visit the **Janssen EMEA** website





The Psoriasis White Paper and the Psoriasis Mandate are supported by Janssen, more specifically Janssen Pharmaceutica NV, Belgium

Date of preparation: August 2013

1. National Rheumatoid Arthritis Society. Fit to Work. Available at: http://www.nras.org.uk/about\_rheumatoid\_arthritis/living\_with\_rl

2. Augustin M, Herberger K, Hintzen S *et al.* Prevalence of skin lesions and need for treatment in a cohort of 90880 workers. *Br* s 3. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, on behalf of the Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. J Invest Dermatol 2013; 133(2): 377-85

4. Ortonne JP, Prinz JC. Alefacept: a novel and selective biologic agent for the treatment of chronic plaque psoriasis. *Eur J Dermatol* 2004,

5. National Psoriasis Foundation. Psoriatic Arthritis. Available at:

6. El-Gabalawy H, Guenther LC, Bernstein CN.